BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Rev Gastroenterol Hepatol 2007;4:78-91. [DOI: 10.1038/ncpgasthep0695] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.4] [Reference Citation Analysis]
Number Citing Articles
1 Biancone L, Onali S, Petruzziello C, Calabrese E, Pallone F. Cancer and immunomodulators in inflammatory bowel diseases. Inflamm Bowel Dis. 2015;21:674-698. [PMID: 25545375 DOI: 10.1097/mib.0000000000000243] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
2 Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2009;15:1837-1843. [PMID: 19462426 DOI: 10.1002/ibd.20974] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
3 Cheerva A, Dillard R, Bertolone S. Extracorporeal photopheresis for the treatment of severe, refractory steroid dependent pediatric Crohn's Disease. J Clin Apher 2013;28:381-6. [PMID: 23720057 DOI: 10.1002/jca.21275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
4 Guandalini S, Cernat E, Moscoso D. Prebiotics and probiotics in irritable bowel syndrome and inflammatory bowel disease in children. Beneficial Microbes 2015;6:209-17. [DOI: 10.3920/bm2014.0067] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
5 Gravina AG, Federico A, Ruocco E, Lo Schiavo A, Romano F, Miranda A, Sgambato D, Dallio M, Ruocco V, Loguercio C, Romano M. Crohn's disease and skin. United European Gastroenterol J 2016;4:165-71. [PMID: 27087942 DOI: 10.1177/2050640615597835] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
6 Kostoff RN. Literature-related discovery: common factors for Parkinson’s Disease and Crohn’s Disease. Scientometrics 2014;100:623-57. [DOI: 10.1007/s11192-014-1298-3] [Cited by in Crossref: 12] [Article Influence: 1.5] [Reference Citation Analysis]
7 Iskandar H, Greer JB, Krasinskas AM, Tinsley AT, Koltun WA, Siegel CA, Levy LC, Herfarth HH, Farraye FA, Binion DG, Rosh JR, Keljo DJ, Isaacs KL, Regueiro MD. IBD LIVE Series-Case 8: Treatment Options for Refractory Esophageal Crohn's Disease and Hidradenitis Suppurativa. Inflamm Bowel Dis 2017;23:1667-77. [PMID: 28906288 DOI: 10.1097/MIB.0000000000001266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Fisher MC, Furer V, Hochberg MC, Greenberg JD, Kremer JM, Curtis JR, Reed G, Harrold L, Solomon DH. Malignancy validation in a United States registry of rheumatoid arthritis patients. BMC Musculoskelet Disord 2012;13:85. [PMID: 22651246 DOI: 10.1186/1471-2474-13-85] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
9 Chang JY, Marks RS, Nagorney DM, Sanderson SO, Kane S. Ulcerative colitis, infliximab, and hepatic epithelioid hemangioendothelioma: who is to blame? Case Report. Therap Adv Gastroenterol 2010;3:203-6. [PMID: 21180602 DOI: 10.1177/1756283X10363015] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
10 Beigel F, Steinborn A, Schnitzler F, Tillack C, Breiteneicher S, John JM, Van Steen K, Laubender RP, Göke B, Seiderer J, Brand S, Ochsenkühn T. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies. Pharmacoepidemiol Drug Saf 2014;23:735-44. [PMID: 24788825 DOI: 10.1002/pds.3621] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
11 Hare NC, Arnott ID, Satsangi J. Therapeutic options in acute severe ulcerative colitis. Expert Review of Gastroenterology & Hepatology 2014;2:357-70. [DOI: 10.1586/17474124.2.3.357] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
12 Nielsen OH, Seidelin JB, Munck LK, Rogler G. Use of biological molecules in the treatment of inflammatory bowel disease. J Intern Med. 2011;270:15-28. [PMID: 21241384 DOI: 10.1111/j.1365-2796.2011.02344.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
13 Sandborn WJ, Rutgeerts P, Feagan BG, Reinisch W, Olson A, Johanns J, Lu J, Horgan K, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab. Gastroenterology 2009;137:1250-60. [DOI: 10.1053/j.gastro.2009.06.061] [Cited by in Crossref: 312] [Cited by in F6Publishing: 291] [Article Influence: 24.0] [Reference Citation Analysis]
14 Kupai K, Almási N, Kósa M, Nemcsók J, Murlasits Z, Török S, Al-awar A, Baráth Z, Pósa A, Varga C. H2S confers colonoprotection against TNBS-induced colitis by HO-1 upregulation in rats. Inflammopharmacol 2018;26:479-89. [DOI: 10.1007/s10787-017-0382-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
15 Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion on Biological Therapy 2016;17:175-84. [DOI: 10.1080/14712598.2017.1271871] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ratcliffe N, Dunbar NM, Adamski J, Couriel D, Edelson R, Kitko CL, Levine JE, Morgan S, Schneiderman J, Sloan S, Wu Y, Szczepiorkowski ZM, Cooling L; American Society for Apheresis. National Institutes of Health State of the Science Symposium in Therapeutic Apheresis: scientific opportunities in extracorporeal photopheresis. Transfus Med Rev. 2015;29:62-70. [PMID: 25459074 DOI: 10.1016/j.tmrv.2014.09.004] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
17 de Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol 2010;7:93-101. [PMID: 20134491 DOI: 10.1038/nrgastro.2009.221] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.8] [Reference Citation Analysis]
18 Biancone L, Zuzzi S, Ranieri M, Petruzziello C, Calabrese E, Onali S, Ascolani M, Zorzi F, Condino G, Iacobelli S. Fistulizing pattern in Crohn’s disease and pancolitis in ulcerative colitis are independent risk factors for cancer: a single-center cohort study. J Crohns Colitis. 2012;6:578-587. [PMID: 22398047 DOI: 10.1016/j.crohns.2011.11.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
19 Rosh JR, Gross T, Mamula P, Griffiths A, Hyams J. Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis. 2007;13:1024-1030. [PMID: 17480018 DOI: 10.1002/ibd.20169] [Cited by in Crossref: 169] [Cited by in F6Publishing: 145] [Article Influence: 11.3] [Reference Citation Analysis]
20 Le PN, Greer JB, Oikonomou I, Schraut WH, Siegel CA, Cross RK, Holubar SD, Tinsley A, Koltun WA, Binion DG, Regueiro MD. IBD LIVE Case Series-Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment? Inflamm Bowel Dis 2015;21:1401-6. [PMID: 25946568 DOI: 10.1097/MIB.0000000000000435] [Reference Citation Analysis]
21 Cucchiara S, Escher JC, Hildebrand H, Amil-dias J, Stronati L, Ruemmele FM. Pediatric Inflammatory Bowel Diseases and the Risk of Lymphoma: Should We Revise Our Treatment Strategies? Journal of Pediatric Gastroenterology & Nutrition 2009;48:257-67. [DOI: 10.1097/mpg.0b013e31818cf555] [Cited by in Crossref: 33] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov 2010;9:325-38. [PMID: 20305665 DOI: 10.1038/nrd3003] [Cited by in Crossref: 551] [Cited by in F6Publishing: 477] [Article Influence: 45.9] [Reference Citation Analysis]
23 Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338-346. [PMID: 19637362 DOI: 10.1002/ibd.20997] [Cited by in Crossref: 146] [Cited by in F6Publishing: 132] [Article Influence: 12.2] [Reference Citation Analysis]
24 Biancone L, Petruzziello C, Orlando A, Kohn A, Ardizzone S, Daperno M, Angelucci E, Castiglione F, D'Incà R, Zorzi F. Cancer in Crohn's Disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758-766. [PMID: 20684009 DOI: 10.1002/ibd.21416] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
25 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
26 Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R. Extracorporeal photopheresis for the treatment of refractory Crohn’s disease: results of an open-label pilot study. Inflamm Bowel Dis. 2009;15:829-836. [PMID: 19130617 DOI: 10.1002/ibd.20833] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
27 Cabré E, Mañosa M, Gassull MA. Omega-3 fatty acids and inflammatory bowel diseases - a systematic review. Br J Nutr 2012;107 Suppl 2:S240-52. [PMID: 22591898 DOI: 10.1017/S0007114512001626] [Cited by in Crossref: 81] [Cited by in F6Publishing: 37] [Article Influence: 8.1] [Reference Citation Analysis]
28 Papa A, Mocci G, Bonizzi M, Felice C, Andrisani G, De Vitis I, Guidi L, Gasbarrini A. Use of infliximab in particular clinical settings: management based on current evidence. Am J Gastroenterol. 2009;104:1575-1586. [PMID: 19491875 DOI: 10.1038/ajg.2009.162] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
29 Leso V, Leggio L, Armuzzi A, Gasbarrini G, Gasbarrini A, Addolorato G. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update: . European Journal of Gastroenterology & Hepatology 2010;22:779-86. [DOI: 10.1097/meg.0b013e328331b654] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
30 Orlando A, Mocciaro F, Civitavecchia G, Scimeca D, Cottone M. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease. Digestive and Liver Disease 2008;40:S236-46. [DOI: 10.1016/s1590-8658(08)60532-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]